Aligos Therapeutics (NASDAQ:ALGS) Sets New 1-Year Low – Here’s What Happened

by · The Cerbat Gem

Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS – Get Free Report) hit a new 52-week low on Tuesday . The company traded as low as $7.20 and last traded at $7.21, with a volume of 18987 shares. The stock had previously closed at $7.50.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $75.00 target price on shares of Aligos Therapeutics in a research report on Friday, September 20th.

Check Out Our Latest Stock Analysis on Aligos Therapeutics

Aligos Therapeutics Trading Down 10.1 %

The stock has a market capitalization of $545.21 million, a PE ratio of -5.81 and a beta of 2.16. The firm has a 50 day moving average of $11.97 and a two-hundred day moving average of $14.95.

Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.00) by $4.75. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. The company had revenue of $1.06 million during the quarter. During the same quarter in the previous year, the firm posted ($10.75) EPS. Equities research analysts forecast that Aligos Therapeutics, Inc. will post -8.2 EPS for the current year.

Hedge Funds Weigh In On Aligos Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Armistice Capital LLC increased its position in Aligos Therapeutics by 5.3% during the 2nd quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock worth $2,540,000 after purchasing an additional 363,000 shares in the last quarter. Acadian Asset Management LLC raised its position in shares of Aligos Therapeutics by 26.1% in the second quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock valued at $289,000 after buying an additional 171,490 shares during the last quarter. Opaleye Management Inc. lifted its stake in shares of Aligos Therapeutics by 25.7% during the first quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock valued at $1,597,000 after buying an additional 333,000 shares during the period. Finally, Altitude Crest Partners Inc. acquired a new stake in Aligos Therapeutics during the fourth quarter worth approximately $1,889,000. Hedge funds and other institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

(Get Free Report)

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).

See Also